keyword
MENU ▼
Read by QxMD icon Read
search

"Health technology assessment"

keyword
https://www.readbyqxmd.com/read/28105986/canagliflozin-dapagliflozin-and-empagliflozin-monotherapy-for-treating-type-2-diabetes-systematic-review-and-economic-evaluation
#1
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O'Hare, David McGrane, Tim Holt, Norman Waugh
BACKGROUND: Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of first choice is metformin. However, some people cannot tolerate metformin, which causes diarrhoea in about 10%, and it cannot be used in people with renal impairment. This review appraises three of the newest class of drugs for monotherapy when metformin cannot be used, the sodium-glucose co-transporter 2 (SGLT2) inhibitors...
January 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28098939/a-systematic-review-of-economic-evaluations-of-treatments-for-patients-with-epilepsy
#2
REVIEW
Ben F M Wijnen, Ghislaine A P G van Mastrigt, Silvia M A A Evers, Olga Gershuni, Danielle A J E Lambrechts, Marian H J M Majoie, Debby Postulart, Bert A P Aldenkamp, Reina J A de Kinderen
The increasing number of treatment options and the high costs associated with epilepsy have fostered the development of economic evaluations in epilepsy. It is important to examine the availability and quality of these economic evaluations and to identify potential research gaps. As well as looking at both pharmacologic (antiepileptic drugs [AEDs]) and nonpharmacologic (e.g., epilepsy surgery, ketogenic diet, vagus nerve stimulation) therapies, this review examines the methodologic quality of the full economic evaluations included...
January 18, 2017: Epilepsia
https://www.readbyqxmd.com/read/28096035/the-role-of-health-economics-in-the-evaluation-of-surgery-and-operative-technologies
#3
Matthew Taylor
Dr Matthew Taylor is the director of York Health Economics Consortium and leads the Consortium's health technology assessment program. The work of York Health Economics Consortium involves empirical research in health economics for both the private and public sectors. Dr Taylor is the scientific lead for the National Institute for Health and Care Excellence (NICE) Economic and Methodological Unit and a former member of NICE's Public Health Advisory Committee. He is also managing director (Europe) of Minerva, an international network of health economics consultancies...
February 2017: Surgery
https://www.readbyqxmd.com/read/28077228/levers-for-addressing-medical-underuse-and-overuse-achieving-high-value-health-care
#4
REVIEW
Adam G Elshaug, Meredith B Rosenthal, John N Lavis, Shannon Brownlee, Harald Schmidt, Somil Nagpal, Peter Littlejohns, Divya Srivastava, Sean Tunis, Vikas Saini
The preceding papers in this Series have outlined how underuse and overuse of health-care services occur within a complex system of health-care production, with a multiplicity of causes. Because poor care is ubiquitous and has considerable consequences for the health and wellbeing of billions of people around the world, remedying this problem is a morally and politically urgent task. Universal health coverage is a key step towards achieving the right care. Therefore, full consideration of potential levers of change must include an upstream perspective-ie, an understanding of the system-level factors that drive overuse and underuse, as well as the various incentives at work during a clinical encounter...
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28073146/value-based-care-in-hepatology
#5
REVIEW
Mario Strazzabosco, John I Allen, Elizabeth O Teisberg
The migration from legacy fee-for-service reimbursement to payments linked to high value health care is accelerating in the United States because of new legislation and re-design of payments from the Centers for Medicare and Medicaid Services (CMS). Since patients with chronic diseases account for substantial use of health care resources, payers and health systems are focusing on maximizing the value of care for these patients. Since chronic liver diseases impose a major health burden worldwide affecting the health and lives of many individuals and families as well as substantial costs for individuals and payers, hepatologists must understand how they can improve their practices ...
January 10, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28065172/incorporating-environmental-outcomes-into-a-health-economic-model
#6
Kevin Marsh, Michael Ganz, Emil Nørtoft, Niels Lund, Joshua Graff-Zivin
OBJECTIVES: Traditional economic evaluations for most health technology assessments (HTAs) have previously not included environmental outcomes. With the growing interest in reducing the environmental impact of human activities, the need to consider how to include environmental outcomes into HTAs has increased. We present a simple method of doing so. METHODS: We adapted an existing clinical-economic model to include environmental outcomes (carbon dioxide [CO2] emissions) to predict the consequences of adding insulin to an oral antidiabetic (OAD) regimen for patients with type 2 diabetes mellitus (T2DM) over 30 years, from the United Kingdom payer perspective...
January 9, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28065169/changing-health-technology-assessment-paradigms-erratum
#7
Don Husereau, Chris Henshall, Laura Sampietro-Colom, Sarah Thomas
In Husereau et al., the affiliation for Laura Sampietro-Colom was listed as "Hospital Clinic". It should have instead been listed as, "Hospital Clinic, Barcelona, Spain".
January 9, 2017: International Journal of Technology Assessment in Health Care
https://www.readbyqxmd.com/read/28063544/the-prevention-of-early-onset-neonatal-group-b-streptococcal-disease
#8
Deborah Money, Victoria M Allen
OBJECTIVE: To review the evidence in the literature and to provide recommendations on the management of pregnant women in labour for the prevention of early-onset neonatal group B streptococcal disease. The key revisions in this updated guideline include changed recommendations for regimens for antibiotic prophylaxis, susceptibility testing, and management of women with pre-labour rupture of membranes. OUTCOMES: Maternal outcomes evaluated included exposure to antibiotics in pregnancy and labour and complications related to antibiotic use...
December 2016: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/28063134/how-can-pricing-and-reimbursement-policies-improve-affordable-access-to-medicines-lessons-learned-from-european-countries
#9
REVIEW
Sabine Vogler, Valérie Paris, Alessandra Ferrario, Veronika J Wirtz, Kees de Joncheere, Peter Schneider, Hanne Bak Pedersen, Guillaume Dedet, Zaheer-Ud-Din Babar
This article discusses pharmaceutical pricing and reimbursement policies in European countries with regard to their ability to ensure affordable access to medicines. A frequently applied pricing policy is external price referencing. While it provides some benchmark for policy-makers and has been shown to be able to generate savings, it may also contribute to delay in product launch in countries where medicine prices are low. Value-based pricing has been proposed as a policy that promotes access while rewarding useful innovation; however, implementing it has proven quite challenging...
January 6, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28062129/-methodological-guideline-for-the-efficacy-and-safety-assessment-of-new-pharmaceuticals-implementation-of-eunethta-s-recommendations
#10
Ruth Ubago Pérez, María Auxiliadora Castillo Muñoz, Mercedes Galván Banqueri, Raúl García Estepa, Eva Rocío Alfaro Lara, María Dolores Vega Coca, Carmen Beltrán Calvo, Teresa Molina López
The European network for Health Technology Assessment (EUnetHTA) is the network of public health technology assessment (HTA) agencies and entities from across the EU. In this context, the HTA Core Model(®), has been developed. The Andalusian Agency for Health Technology Assessment (AETSA) is a member of the Spanish HTA Network and EUnetHTA collaboration In addition, AETSA participates in the new EUnetHTA Joint Action 3 (JA, 2016-2019). Furthermore, AETSA works on pharmaceutical assessments. Part of this work involves drafting therapeutic positioning reports (TPRs) on drugs that have recently been granted marketing authorisation, which is overseen by the Spanish Agency of Medicines and Medical Devices (AEMPS)...
January 3, 2017: Gaceta Sanitaria
https://www.readbyqxmd.com/read/28061042/assessing-the-expected-value-of-research-studies-in-reducing-uncertainty-and-improving-implementation-dynamics
#11
Sabine E Grimm, Simon Dixon, John W Stevens
BACKGROUND: With low implementation of cost-effective health technologies being a problem in many health systems, it is worth considering the potential effects of research on implementation at the time of health technology assessment. Meaningful and realistic implementation estimates must be of dynamic nature. OBJECTIVE: To extend existing methods for assessing the value of research studies in terms of both reduction of uncertainty and improvement in implementation by considering diffusion based on expert beliefs with and without further research conditional on the strength of evidence...
January 1, 2017: Medical Decision Making: An International Journal of the Society for Medical Decision Making
https://www.readbyqxmd.com/read/28059054/randomised-controlled-trial-evaluating-the-effectiveness-and-cost-effectiveness-of-families-for-health-a-family-based-childhood-obesity-treatment-intervention-delivered-in-a-community-setting-for-ages-6-to-11-years
#12
Wendy Robertson, Joanna Fleming, Atiya Kamal, Thomas Hamborg, Kamran A Khan, Frances Griffiths, Sarah Stewart-Brown, Nigel Stallard, Stavros Petrou, Douglas Simkiss, Elizabeth Harrison, Sung Wook Kim, Margaret Thorogood
BACKGROUND: Effective programmes to help children manage their weight are required. 'Families for Health' focuses on a parenting approach, designed to help parents develop their parenting skills to support lifestyle change within the family. Families for Health version 1 showed sustained reductions in mean body mass index (BMI) z-score after 2 years in a pilot project. OBJECTIVE: The aim was to evaluate its effectiveness and cost-effectiveness in a randomised controlled trial (RCT)...
January 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28057183/immunoth%C3%A3-rapie-une-innovation-de-rupture-non-soutenable-%C3%A3-conomiquement
#13
Jean-Pierre Thierry
A NON-SUSTAINABLE BREAKTHROUGH?: The arrival of new immunotherapy anticancer drugs on the market marks a turning point. Their reference prices are fixed in the US and are positioned at the same level that the anticancer targeted therapies. They benefit from an accelerated approval process and often obtain the status of orphan drugs. The extensions of indications to many cancers and the likely combinations could significantly increase healthcare spending at a level that recently unveiled their non-sustainability, due to unrealistic prices approved by regulators...
November 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/28052810/clinical-effectiveness-and-cost-effectiveness-of-surgical-options-for-the-management-of-anterior-and-or-posterior-vaginal-wall-prolapse-two-randomised-controlled-trials-within-a-comprehensive-cohort-study-results-from-the-prospect-study
#14
Cathryn Glazener, Suzanne Breeman, Andrew Elders, Christine Hemming, Kevin Cooper, Robert Freeman, Anthony Smith, Suzanne Hagen, Isobel Montgomery, Mary Kilonzo, Dwayne Boyers, Alison McDonald, Gladys McPherson, Graeme MacLennan, John Norrie
BACKGROUND: The use of mesh in prolapse surgery is controversial, leading to a number of enquiries into its safety and efficacy. OBJECTIVE: To compare synthetic non-absorbable mesh inlay, biological graft and mesh kit with a standard repair in terms of clinical effectiveness, adverse effects, quality of life (QoL), costs and cost-effectiveness. DESIGN: Two randomised controlled trials within a comprehensive cohort (CC) study. Allocation was by a remote web-based randomisation system in a 1 :1 : 1 ratio (Primary trial) or 1 : 1 : 2 ratio (Secondary trial), and was minimised on age, type of prolapse repair planned, need for a concomitant continence procedure, need for a concomitant upper vaginal prolapse procedure and surgeon...
December 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28051764/the-use-of-fibrin-sealant-during-non-emergency-surgery-a-systematic-review-of-evidence-of-benefits-and-harms
#15
Steven J Edwards, Fay Crawford, Michelle Helena van Velthoven, Andrea Berardi, George Osei-Assibey, Mariana Bacelar, Fatima Salih, Victoria Wakefield
BACKGROUND: Fibrin sealants are used in different types of surgery to prevent the accumulation of post-operative fluid (seroma) or blood (haematoma) or to arrest haemorrhage (bleeding). However, there is uncertainty around the benefits and harms of fibrin sealant use. OBJECTIVES: To systematically review the evidence on the benefits and harms of fibrin sealants in non-emergency surgery in adults. DATA SOURCES: Electronic databases [MEDLINE, EMBASE and The Cochrane Library (including the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Health Technology Assessment database and the Cochrane Central Register of Controlled Trials)] were searched from inception to May 2015...
December 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28035842/clinical-and-cost-implications-of-beta-amyloid-detection-with-a%C3%AE-pet-imaging-in-early-alzheimer-s-disease-the-case-of-florbetapir
#16
John Hornberger, Jay Bae, Ian Watson, Joe Johnston, Michael Happich
OBJECTIVE: Amyloid-β (Aβ) positron emission tomography (PET) imaging helps estimate Aβ neuritic plaque density in patients with cognitive impairment who are under evaluation for Alzheimer's disease (AD). This study aims to evaluate the cost-effectiveness of the Aβ-PET scan as an adjunct to standard diagnostic assessment for diagnosis of AD in France, using florbetapir as an example. METHODS: A state-transition probability analysis was developed adopting the French Health Technology Assessment (HTA) perspective per guidance...
December 30, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28033447/assessment-of-overall-survival-quality-of-life-and-safety-benefits-associated-with-new-cancer-medicines
#17
Sebastian Salas-Vega, Othon Iliopoulos, Elias Mossialos
Importance: There is a dearth of evidence examining the impact of newly licensed cancer medicines on therapy. This information could otherwise support clinical practice, and promote value-based decision-making in the cancer drug market. Objective: To evaluate the comparative therapeutic value of all new cancer medicines approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) between 2003 and 2013. Design, Setting, and Participants: We used a narrative synthesis approach to systematically synthesize and analyze English, French, and Australian health technology assessments (HTAs) of all new cancer medicines licensed in the United States and Europe between 2003 and 2013...
December 29, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/28029415/relating-health-technology-assessment-recommendations-and-reimbursement-decisions-in-poland-in-years-2012-2014-a-retrospective-analysis
#18
Paweł Kawalec, Krzysztof Piotr Malinowski
OBJECTIVE: The aim of the study was to assess the influence of public advisory bodies (the Transparency Council, the President of the AOTMiT; The Polish Agency for Health Technology Assessment and Tarff System) involved in the process on final reimbursement decisions performed by the Ministry of Health. METHODS: We have analysed all statements of the Transparency Council as well as the President of the AOTMiT recommendations and final reimbursement decisions in Poland for the period of three years: 2012 till 2014...
October 11, 2016: Health Policy
https://www.readbyqxmd.com/read/28029401/-equity-informative-health-technology-assessment-a-commentary-on-ngalesoni-ruhago-mori-robberstad-norheim
#19
Richard Cookson
No abstract text is available yet for this article.
October 24, 2016: Social Science & Medicine
https://www.readbyqxmd.com/read/28029334/patient-reported-outcomes-in-rare-lysosomal-storage-diseases-key-informant-interviews-and-a-systematic-review-protocol
#20
Patricia A Miller, Sohail M Mulla, Thomasin Adams-Webber, Yasmin Sivji, Gordon H Guyatt, Bradley C Johnston
OBJECTIVES: To investigate the use, challenges and opportunities associated with using patient-reported outcomes (PROs) in studies with patients with rare lysosomal storage diseases (LSDs), we conducted interviews with researchers and health technology assessment (HTA) experts, and developed the methods for a systematic review of the literature. The purpose of the review is to identify the psychometrically sound generic and disease-specific PROs used in studies with patients with five LSDs of interest: Fabry, Gaucher (Type I), Niemann-Pick (Type B) and Pompe diseases, and mucopolysaccharidosis (Types I and II)...
December 28, 2016: International Journal of Technology Assessment in Health Care
keyword
keyword
9540
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"